Mersana Therapeutics Inc. (MRSN)

The total asset value of Mersana Therapeutics Inc. (MRSN) stood at $ 386 Mln as on 30-Jun-23

The share price of Mersana Therapeutics Inc. (MRSN) is $2.04 (NASDAQ) as of 04-Dec-2023 16:05 EST. Mersana Therapeutics Inc. (MRSN) has given a return of -55.4% in the last 3 years.

Mersana Therapeutics Inc. (MRSN) has a market capitalisation of $ 143 Mln as on 11-Aug-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Mersana Therapeutics Inc. (MRSN) is 7.14 times as on 11-Aug-2023, a 1.81% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Mersana Therapeutics Inc. (MRSN) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mersana Therapeutics Inc. (MRSN) and enter the required number of quantities and click on buy to purchase the shares of Mersana Therapeutics Inc. (MRSN).

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

The CEO & director of Ms. Anna Protopapas M.B.A.. is Mersana Therapeutics Inc. (MRSN), and CFO & Sr. VP is Mr. Brian C. DeSchuytner.

The promoters of Mersana Therapeutics Inc. (MRSN) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of Mersana Therapeutics Inc. (MRSN) was $-170 Mln.